YS Biopharma Co., Ltd. announced that the United States Patent and Trademark Office has issued it a patent covering the Company's PIKA YS-HBV-002, an immunotherapeutic vaccine designed to treat patients suffering from chronic hepatitis B virus ("HBV") infection. YS Biopharma expects to submit an Investigational New Drug (IND) application and commence the clinical development of PIKA YS- HBV-002 as a novel immunotherapy for the treatment of chronic HBV infection in 2024. According to the American Liver Foundation, it is estimated that between 850,000 and 2.2 million people suffer from chronic HBV infection in the United States.

Worldwide, nearly two billion people are hepatitis B carriers, and about 400 million suffer from chronic HBV infection according to the European Association for the Study of the Liver. This latest patent underscores the dedication to innovation and commitment to enhancing treatment options for patients around the world. PIKA YS-BHBV-002 vaccine has the potential to advance the fight against chronic HBV infection, a hugely significant unaddressed medical need in the United States and across the globe.

This clinical candidate is based on the advancement of multiple components from preclinical and clinical studies, and are now focused on progressing it to clinical trials.